

# EMERGENT

## Emergent BioSolutions to Participate in Investor Conferences

March 14, 2022

GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:

- **KeyBanc Life Sciences & MedTech Investor Forum**

March 22, 2022

Company fireside chat scheduled for 1:30 pm eastern

<https://wsw.com/webcast/key21/ebs/1521976>

- **BofA Securities 2022 Healthcare Conference**

May 10, 2022

Presentation scheduled for 12:00 pm eastern

- **Goldman Sachs 7th Annual Leveraged Finance and Credit Conference**

May 11 to 13, 2022

Presentation date and time will be updated on the Emergent website as the information becomes available.

For conferences where a presentation is planned, the company's webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the [Emergent website](#).

### About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For over 20 years, we've been at work defending people from things we hope will never happen—so we are prepared, just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our [website](#) and follow us on [LinkedIn](#), [Twitter](#), and [Instagram](#).

### Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

[burrowsr@ebsi.com](mailto:burrowsr@ebsi.com)

### Media Contact:

Matt Hartwig

Senior Director, Media Relations

[mediarelations@ebsi.com](mailto:mediarelations@ebsi.com)

# EMERGENT

Source: Emergent BioSolutions